PsychoGenics is a Preclinical CRO with expertise in the CNS and orphan disorders. They are known for their cutting edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for their ability to identify statistically relevant phenotypic changes, even early and subtle changes, that help clients quantify the efficacy of their treatments before they move into the clinic.
With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, PsychoGenics enables clients to deliver superior clinical candidates.
The Company’s capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. Complementing its extensive capabilities, PsychoGenics offers a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders.
Their team of experts includes more than 30 highly trained PhD scientists from around the world with a deep understanding of preclinical research and expertise in the fields of behavior, electrophysiology, bioanalysis, molecular biology and informatics. Their scientists engage in the design and execution of preclinical drug development program using their AAALAC approved animal facilities, proprietary animal models, and extensive capabilities. They pride themselves on the quality of their work and completing projects on time.
Their state-of-the-art animal vivaria cover over 70,000 square feet and are all AAALAC accredited.
PsychoGenics has pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube®, NeuroCube®, and PhenoCube® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.See more